Filing Flows › Kura Oncology (KURA) › Q1 2026
Kura Oncology (KURA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Kura Oncology (KURA) reported revenue of $18.3M for the first quarter 2026 (Q1 2026), +29% from a year earlier and +5% from the quarter before. Operating margin was -431.5%, net loss $73.3M (401.5% of revenue).
Kura Oncology, Q1 2026: revenue $18.3M (+30% year over year), operating margin -431.5%, net loss $73.3M, operating cash flow −$85.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.3M | +5% | +29% |
| Operating profit | −$78.8M | — | — |
| Net earnings | −$73.3M | — | — |
| Operating cash flow | −$85.9M | -173% | — |
What changed
Revenue was $18.3M in Q1 2026, up 29% year over year and up 5% from the previous quarter. License and Collaboration Revenue was the largest line at 68% of revenue. License and Collaboration Revenue declined 11%.
Operating costs exceeded revenue by $78.8M, an operating margin of -431.5%. Total costs grew 23% against revenue growth of 29%. The fastest-growing cost line was SG&A (+38%). The quarter ended with a net loss of $73.3M, narrower than the previous quarter's $81.0M loss.
Operating cash flow was −$85.9M. Non-cash charges added back $355K of depreciation and $8.4M of share-based compensation. Working capital and other items used $21.3M. Capital expenditures of $128K exceeded it, leaving free cash flow of −$86.0M.
Questions
What was Kura Oncology's revenue in the first quarter 2026?
Kura Oncology (KURA) reported revenue of $18.3M for the first quarter 2026 (Q1 2026), +29% from a year earlier and +5% from the quarter before.
Was Kura Oncology profitable in the first quarter 2026?
Operating loss was $78.8M (-431.5% of revenue) and net loss $73.3M.
Source: Kura Oncology 10-Q on SEC EDGAR.